Bulk Pharmaceutical API Sources for chlorphenesin carbamate

Bulk Pharmaceutical API Sources for chlorphenesin carbamate

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		2724
MP Biomedicals		150662
MolPort		MolPort-002-070-331
AAA Chemistry		AR-1E6833

Bulk Active Pharmaceutical Ingredient (API) Sources for Chlorphenesin Carbamate

Last updated: February 19, 2026

This analysis identifies and evaluates key global suppliers of bulk chlorphenesin carbamate API. It examines manufacturing capabilities, regulatory compliance, and market presence to inform procurement and investment decisions.

What is Chlorphenesin Carbamate?

Chlorphenesin carbamate is a muscle relaxant. It acts centrally to relieve muscle spasms. Its mechanism of action involves inhibiting polysynaptic reflexes. The compound is chemically known as 1-(4-chlorophenoxy)-2,3-propanediol dicarbamate. It is primarily used in the treatment of acute, painful musculoskeletal conditions. This includes muscle strains, sprains, and spasms. The typical oral dosage ranges from 400 mg to 800 mg three times daily. Its efficacy is comparable to other muscle relaxants like cyclobenzaprine and carisoprodol. However, its side effect profile can differ. Common side effects include drowsiness, dizziness, and gastrointestinal upset. It is metabolized in the liver and excreted in the urine.

Global API Manufacturing Landscape

The production of chlorphenesin carbamate API is concentrated among a limited number of manufacturers, primarily located in Asia. These suppliers cater to both generic and branded pharmaceutical markets. Key considerations for sourcing include Good Manufacturing Practice (GMP) compliance, regulatory filings with agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and consistent quality control. Supply chain stability and cost-effectiveness are also critical factors for pharmaceutical companies.

Key Manufacturers and Their Capabilities

Several companies have established themselves as significant suppliers of chlorphenesin carbamate API.

• Anand Synthetics (India): Anand Synthetics is a prominent Indian manufacturer of Active Pharmaceutical Ingredients. The company produces a range of APIs, including muscle relaxants. Their manufacturing facilities are certified under various international quality standards, including WHO-GMP. They export to numerous regulated and semi-regulated markets. Anand Synthetics focuses on process optimization to ensure cost-effective production while maintaining high purity standards. Their annual production capacity for APIs is significant, although specific figures for chlorphenesin carbamate are proprietary. They have a robust quality management system in place.
• Divi's Laboratories (India): Divi's Laboratories is a leading global producer of APIs and intermediates. While Divi's is known for its large-scale production of various complex molecules, chlorphenesin carbamate is not a primary product listed in their public portfolio. However, their extensive manufacturing infrastructure and expertise in custom synthesis suggest potential capability. Divi's adheres to stringent cGMP standards and has a strong regulatory track record with FDA and EMA. Their emphasis on backward integration ensures control over raw material quality and supply.
• Lupin Ltd. (India): Lupin is a major global pharmaceutical company with significant API manufacturing capabilities. While their primary focus is on finished dosage forms, they also produce APIs for internal consumption and external sales. Their regulatory compliance is robust, with multiple FDA-approved manufacturing sites. Specific details on their chlorphenesin carbamate API production are not readily available, but their broad API portfolio indicates potential.
• Asclepius Pharma (India): Asclepius Pharma specializes in the development and manufacturing of niche APIs. They have a dedicated research and development team focused on process chemistry and scale-up. Their manufacturing site operates under cGMP guidelines. They aim to supply APIs to global markets, emphasizing quality and regulatory adherence. Information regarding their specific production volumes of chlorphenesin carbamate is not publicly disclosed.
• Jiangsu HEC Pharma (China): Jiangsu HEC Pharma is a significant player in the Chinese pharmaceutical ingredients market. They are known for producing a wide array of APIs. Their manufacturing facilities are designed to meet international quality standards, and they are a common supplier to companies worldwide. Their focus on continuous improvement and technological innovation supports their competitive position. Data on their specific chlorphenesin carbamate output is not publicly available, but their broad API range includes similar chemical classes.
• Sichuan Kelun Pharmaceutical (China): Sichuan Kelun Pharmaceutical is a large pharmaceutical conglomerate in China with substantial API manufacturing capacity. They are involved in research, development, manufacturing, and sales of pharmaceutical products. Their API division is a key component, serving both domestic and international markets. They possess advanced manufacturing technology and adhere to GMP standards. Information on specific chlorphenesin carbamate production is not detailed in their public disclosures.

Comparative Analysis of Key Suppliers

Manufacturer	Country of Origin	Primary Product Focus	Regulatory Approvals (examples)	Notes
Anand Synthetics	India	Diverse APIs, including muscle relaxants	WHO-GMP	Strong focus on cost-effectiveness and quality for regulated and semi-regulated markets.
Divi's Laboratories	India	Complex APIs, intermediates, custom synthesis	FDA, EMA	Extensive infrastructure; potential capability for chlorphenesin carbamate production via custom synthesis.
Lupin Ltd.	India	Finished dosage forms, APIs for internal/external sales	FDA	Broad API portfolio, indicating potential for this molecule.
Asclepius Pharma	India	Niche APIs, custom synthesis	cGMP	Focus on quality and regulatory adherence for global markets.
Jiangsu HEC Pharma	China	Wide range of APIs	Local/International Standards	Significant player in the Chinese API market, serving global clients.
Sichuan Kelun Pharma	China	Diverse APIs, intermediates	Local/International Standards	Large-scale operations with a broad API portfolio.

Regulatory Landscape and Quality Standards

The production of pharmaceutical APIs is strictly regulated to ensure patient safety and product efficacy. Manufacturers must adhere to Good Manufacturing Practices (GMP). These practices cover all aspects of production, from raw material sourcing and manufacturing processes to quality control and documentation.

• Current Good Manufacturing Practices (cGMP): Mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), cGMP ensures that products are consistently produced and controlled according to quality standards. This includes requirements for facility design, equipment calibration, personnel training, process validation, and record-keeping.
• Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, and quality controls used in the manufacturing, processing, packaging, and storing of an API. Pharmaceutical companies that use the API can reference the DMF in their drug applications without having direct access to the proprietary information.
• Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing facilities to ensure compliance with GMP. Pharmaceutical companies also conduct their own audits of potential suppliers to verify quality systems and manufacturing capabilities.
• Pharmacopoeial Standards: APIs must meet the specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). These standards define identity, strength, quality, and purity criteria.

The ability of an API manufacturer to provide comprehensive documentation, including Certificates of Analysis (CoAs), stability data, and impurity profiles, is critical for pharmaceutical companies seeking to register and market finished drug products. Manufacturers with a proven track record of successful regulatory inspections and filings are generally preferred.

Market Dynamics and Supply Chain Considerations

The market for chlorphenesin carbamate API is influenced by several factors:

• Generic Competition: As chlorphenesin carbamate is an off-patent drug, the market is largely driven by generic manufacturers. This creates price pressure on API suppliers.
• Demand Fluctuations: Demand for chlorphenesin carbamate can fluctuate based on prescribing patterns for muscle relaxants, seasonal factors affecting musculoskeletal injuries, and the availability of alternative treatments.
• Geopolitical Factors: Trade policies, tariffs, and geopolitical instability can impact global supply chains, affecting the cost and availability of raw materials and finished APIs.
• Raw Material Sourcing: The synthesis of chlorphenesin carbamate requires specific chemical precursors. The availability and cost of these raw materials can significantly influence the final API price and production reliability.
• Intellectual Property: While the primary compound is off-patent, there may be patents related to specific manufacturing processes, polymorphic forms, or novel formulations that could impact market entry or competition.

Companies seeking to secure a reliable supply of chlorphenesin carbamate API should consider:

1. Supplier Qualification: Thoroughly vet potential suppliers through audits, review of quality documentation, and assessment of their regulatory history.
2. Supply Chain Diversification: Avoid single-source dependency. Identify and qualify at least two reliable suppliers to mitigate risks associated with disruptions.
3. Contractual Agreements: Establish clear supply agreements that define quality specifications, pricing, delivery schedules, and contingency plans.
4. Quality Control Testing: Implement robust incoming quality control testing for each API batch received to verify compliance with established specifications.

Key Takeaways

• Global production of chlorphenesin carbamate API is primarily centered in India and China, with established manufacturers demonstrating varying degrees of specialization and market reach.
• Anand Synthetics, a prominent Indian manufacturer, is identified as a key supplier with a focus on quality and cost-effectiveness for diverse global markets.
• Regulatory compliance, including adherence to cGMP standards and the availability of DMFs, is paramount for API suppliers. Manufacturers with a strong regulatory history with agencies like the FDA and EMA are preferred.
• The market is characterized by generic competition, leading to price sensitivity. Supply chain diversification and rigorous supplier qualification are essential for securing reliable and cost-effective sourcing.
• Consideration of raw material sourcing, geopolitical risks, and potential process-related intellectual property is critical for strategic procurement.

Frequently Asked Questions

What are the primary regulatory bodies that oversee chlorphenesin carbamate API manufacturing?

The primary regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory authorities in other major markets. These agencies enforce Current Good Manufacturing Practices (cGMP) and review Drug Master Files (DMFs).

How can a pharmaceutical company verify the quality of bulk chlorphenesin carbamate API from a new supplier?

Verification involves thorough supplier qualification processes, including on-site audits of manufacturing facilities, review of quality management systems, inspection of batch records and Certificates of Analysis (CoAs), and independent laboratory testing of API samples to confirm compliance with pharmacopoeial standards and internal specifications.

What is the typical shelf life for bulk chlorphenesin carbamate API, and how is it determined?

The typical shelf life for chlorphenesin carbamate API is usually determined through formal stability studies conducted by the manufacturer. These studies assess the API's physical and chemical integrity under defined storage conditions (e.g., temperature, humidity, light) over time, often following ICH guidelines. A common shelf life might range from 2 to 5 years, but this must be confirmed by the manufacturer's specific data.

Are there any significant patent restrictions on the manufacturing of generic chlorphenesin carbamate API?

As chlorphenesin carbamate itself is an off-patent molecule, there are generally no broad patent restrictions on its basic manufacturing. However, specific process patents or patents on novel polymorphic forms or enantioselective synthesis routes could exist and may require careful evaluation by generic manufacturers to ensure freedom to operate.

What are the key raw materials involved in the synthesis of chlorphenesin carbamate, and do their supply chains present any particular risks?

Key raw materials typically include 4-chlorophenol and epichlorohydrin, which are then reacted and subsequently carbamoylated. Risks in their supply chains can arise from the availability and pricing volatility of these basic chemicals, which are often produced in large petrochemical complexes. Geopolitical factors affecting regions with significant chemical production, as well as environmental regulations impacting their manufacturing, can also pose supply risks.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs—Submitting Manufacturing Concerns. Retrieved from https://www.fda.gov/ (General reference for regulatory processes)

[2] European Medicines Agency. (n.d.). Active substances (AS). Retrieved from https://www.ema.europa.eu/ (General reference for EU regulatory processes)

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Quality Guidelines. Retrieved from https://www.ich.org/ (Reference for stability testing guidelines)

[4] Anand Synthetics. (n.d.). Product Portfolio. Retrieved from https://www.anandsynthetics.com/ (Information on manufacturer capabilities)

[5] Divi's Laboratories. (n.d.). Our Businesses. Retrieved from https://www.divislabs.com/ (Information on manufacturer capabilities)

[6] Lupin Ltd. (n.d.). API Business. Retrieved from https://www.lupin.com/ (Information on manufacturer capabilities)